Form 4: Fennec Pharmaceuticals Director Chris Rallis Reports Stock Transactions

Director Chris Rallis of Fennec Pharmaceuticals reports exercising options and selling shares to cover tax obligations under a pre-arranged 10b5-1 trading plan.

Summary

• On April 11, 2025, Chris Rallis, a director of Fennec Pharmaceuticals, exercised options to acquire 2,173 common shares at a price of $2.3.
• Following the exercise, Rallis sold 1,409 shares at $4.95 to satisfy tax obligations related to the option exercise.
• After these transactions, Rallis beneficially owns 53,784 common shares.
• The option exercise was conducted under a 10b5-1 trading plan adopted on August 17, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing plan, with no indication of positive or negative implications for the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a lack of insider information influencing the trades.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares available in the market.

Key Dates

Keywords

Fennec Pharmaceuticals, Chris Rallis, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Director, Beneficial Ownership